Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

B. Bikdeli; M. Madhavan; A. Gupta; D. Jimenez; J. Burton; N. Der; T. Chuich; S. Nouri; I. Dreyfus; E. Driggin; S. Sethi; K. Sehgal; S. Chatterjee; W. Ageno; M. Madjid; Y. Guo; L. Tang; Y. Hu; L. Bertoletti; J. Giri; M. Cushman; I. Quéré; E. Dimakakos; C. Gibson; G. Lippi; E. Favaloro; J. Fareed; A. Tafur; D. Francese; J. Batra; A. Falanga; K. Clerkin; N. Uriel; A. Kirtane; C. McLintock; B. Hunt; A. Spyropoulos; G. Barnes; J. Eikelboom; I. Weinberg; S. Schulman; M. Carrier; G. Piazza; J. Beckman; M. Leon; G. Stone; S. Rosenkranz; S. Goldhaber; S. Parikh; M. Monreal; H. Krumholz; S. Konstantinides; J. Weitz; G. Lip

Статья

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

B. Bikdeli, M. Madhavan, A. Gupta, D. Jimenez, J. Burton, N. Der, T. Chuich, S. Nouri, I. Dreyfus, E. Driggin, S. Sethi, K. Sehgal, S. Chatterjee, W. Ageno, M. Madjid, Y. Guo, L. Tang, Y. Hu, L. Bertoletti, J. Giri, M. Cushman, I. Quéré, E. Dimakakos, C. Gibson, G. Lippi, E. Favaloro, J. Fareed, A. Tafur, D. Francese, J. Batra, A. Falanga, K. Clerkin, N. Uriel, A. Kirtane, C. McLintock, B. Hunt, A. Spyropoulos, G. Barnes, J. Eikelboom, I. Weinberg, S. Schulman, M. Carrier, G. Piazza, J. Beckman, M. Leon, G. Stone, S. Rosenkranz, S. Goldhaber, S. Parikh, M. Monreal, H. Krumholz, S. Konstantinides, J. Weitz, G. Lip,

2021

https://doi.org/10.1055/s-0040-1713152

Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19. © 2020 Georg Thieme Verlag KG Stuttgart New York.

Цитирование

Источник

Версии

1. Version of Record от 2021-04-27

Метаданные

Об авторах

B. Bikdeli
New York-Presbyterian Hospital, Columbia University Irving Medical Center, 622 West 168th St, PH 3-347, New York, NY 10032, United States
M. Madhavan
Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, CT, United States
A. Gupta
Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, United States
D. Jimenez
Respiratory Department, Hospital Ramón y Cajal, Madrid, Spain
J. Burton
Medicine Department, Universidad de Alcalá (IRYCIS), Ciber de Enfermedades Respiratorias (CIBERES), Madrid, Spain
N. Der
Harvard Medical School, Boston, MA, United States
T. Chuich
Beth Israel Deaconess Medical Center, Boston, MA, United States
S. Nouri
North Shore and Long Island Jewish University Hospitals, Queens, NY, United States
I. Dreyfus
Department of Medicine and Surgery, University of Insubria, Varese, Italy
E. Driggin
McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States
S. Sethi
Department of Cardiology, Chinese Pla General Hospital, Beijing, China
K. Sehgal
Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
S. Chatterjee
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
W. Ageno
Department of Médecine Vasculaire et Thérapeutique, Cic 1408, Innovte, Chu de St-Etienne, Inserm UMR1059, Université Jean-Monnet, Saint-Etienne, France
M. Madjid
Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, PA, United States
Y. Guo
Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, United States
L. Tang
Corporal Michael J. Crescenz Va Medical Center, Philadelphia, PA, United States
Y. Hu
Larner College of Medicine, University of Vermont, Burlington, VT, United States
L. Bertoletti
Department of Vascular Medicine, University of Montpellier, Montpellier Chu, InnoVTE F-CRIN Network, Montpellier, France
J. Giri
Oncology Unit Gpp, Sotiria General Hospital, Athens School of Medicine, Athens, Greece
M. Cushman
Laboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy
I. Quéré
Laboratory Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Nsw Health Pathology, Westmead Hospital, Westmead, NSW, Australia
E. Dimakakos
Sydney Centres for Thrombosis and Haemostasis, Westmead, NSW, Australia
C. Gibson
Loyola University Medical Center, Chicago, IL, United States
G. Lippi
Pritzker School of Medicine, University of Chicago, Chicago, IL, United States
E. Favaloro
Division of Vascular Medicine, Department of Medicine, NorthShore University HealthSystem, Skokie, IL, United States
J. Fareed
Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni Xxiii, University of Milan Bicocca, Bergamo, Italy
A. Tafur
Auckland City Hospital, Auckland, New Zealand
D. Francese
St Thomas' Hospital, London, United Kingdom
J. Batra
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, United States
A. Falanga
Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, United States
K. Clerkin
Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, United States
N. Uriel
Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
A. Kirtane
Massachusetts General Hospital, Boston, MA, United States
C. McLintock
Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
B. Hunt
McMaster University, Hamilton, ON, Canada
A. Spyropoulos
Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
G. Barnes
Ottawa Hospital Research Institute, Ottawa, ON, Canada
J. Eikelboom
Brigham and Women's Hospital, Boston, MA, United States
I. Weinberg
Vanderbilt University School of Medicine, Nashville, TN, United States
S. Schulman
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
M. Carrier
Department of Cardiology, Cologne Cardiovascular Research Center (CCRC), Heart Center, University of Cologne, Cologne, Germany
G. Piazza
Department of Internal Medicine, Hospital Universitari Germans Trials i Pujol, Universidad Católica de Murcia, Barcelona, Spain
J. Beckman
Department of Health Policy and Administration, Yale School of Public Health, New Haven, CT, United States
M. Leon
Section of Cardiovascular Medicine, Department of Internal Medicie, Yale School of Medicine, New Haven, CT, United States
G. Stone
Center for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany
S. Rosenkranz
Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark
S. Goldhaber
S. Parikh
M. Monreal
H. Krumholz
S. Konstantinides
J. Weitz
G. Lip

Название журнала

Thrombosis and Haemostasis

Том

Выпуск

Страницы

1004-1024

Ключевые слова

acetylsalicylic acid; alteplase; angiotensin converting enzyme 2; antithrombin; danaparoid; dipyridamole; drotrecogin; glucocorticoid; hydroxychloroquine; immunoglobulin enhancer binding protein; interleukin 6; recombinant thrombomodulin; rivaroxaban; sulodexide; ticagrelor; tocilizumab; urokinase; von Willebrand factor; vorapaxar; anticoagulant agent; antiinflammatory agent; antithrombocytic agent; antivirus agent; fibrinolytic agent; glycosaminoglycan; sulodexide; activated partial thromboplastin time; acute coronary syndrome; adult respiratory distress syndrome; bleeding; clinical trial (topic); coronavirus disease 2019; cytokine release; human; immunomodulation; inflammation; mortality; nonhuman; platelet count; priority journal; Review; Severe acute respiratory syndrome coronavirus 2; thrombocyte aggregation; thromboinflammation; thromboinflammation; thrombosis; venous thromboembolism; animal; Betacoronavirus; complication; Coronavirus infection; hemostasis; immunology; inflammation; pandemic; thrombosis; virus pneumonia; Animals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia, Viral; Thrombosis

Издатель

Georg Thieme Verlag

Тип документа

Review

Источник

scopus

Поиск по репозиторию

Статья

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

Похожие публикации

Источник

Версии

Метаданные